Charcot–Marie–Tooth disease type 2A (CMT2A) is a rare inherited axonal neuropathy caused by mutations in MFN2 gene, which encodes Mitofusin 2, a transmembrane protein of the outer mitochondrial membrane. We performed a cross-sectional analysis on thirteen patients carrying mutations in MFN2, from ten families, describing their clinical and genetic characteristics. Evaluated patients presented a variable age of onset and a wide phenotypic spectrum, with most patients presenting a severe phenotype. A novel heterozygous missense variant was detected, p.K357E. It is located at a highly conserved position and predicted as pathogenic by in silico tools. At a clinical level, the p.K357E carrier shows a severe sensorimotor axonal neuropathy. In conclusion, our work expands the genetic spectrum of CMT2A, disclosing a novel mutation and its related clinical effect, and provides a detailed description of the clinical features of a cohort of patients with MFN2 mutations. Obtaining a precise genetic diagnosis in affected families is crucial both for family planning and prenatal diagnosis, and in a therapeutic perspective, as we are entering the era of personalized therapy for genetic diseases.
Clinical and genetic features of a cohort of patients with MFN2-related neuropathy / E. Abati, A. Manini, D. Velardo, R. Del Bo, L. Napoli, F. Rizzo, M. Moggio, N. Bresolin, E. Bellone, M.T. Bassi, M.G. D'Angelo, G.P. Comi, S. Corti. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 12:1(2022 Apr 13), pp. 6181.1-6181.8. [10.1038/s41598-022-10220-0]
Clinical and genetic features of a cohort of patients with MFN2-related neuropathy
E. Abati
Primo
;A. Manini;R. Del Bo;F. Rizzo;N. Bresolin;E. Bellone;M.T. Bassi;M.G. D'Angelo;G.P. ComiPenultimo
;S. CortiUltimo
2022
Abstract
Charcot–Marie–Tooth disease type 2A (CMT2A) is a rare inherited axonal neuropathy caused by mutations in MFN2 gene, which encodes Mitofusin 2, a transmembrane protein of the outer mitochondrial membrane. We performed a cross-sectional analysis on thirteen patients carrying mutations in MFN2, from ten families, describing their clinical and genetic characteristics. Evaluated patients presented a variable age of onset and a wide phenotypic spectrum, with most patients presenting a severe phenotype. A novel heterozygous missense variant was detected, p.K357E. It is located at a highly conserved position and predicted as pathogenic by in silico tools. At a clinical level, the p.K357E carrier shows a severe sensorimotor axonal neuropathy. In conclusion, our work expands the genetic spectrum of CMT2A, disclosing a novel mutation and its related clinical effect, and provides a detailed description of the clinical features of a cohort of patients with MFN2 mutations. Obtaining a precise genetic diagnosis in affected families is crucial both for family planning and prenatal diagnosis, and in a therapeutic perspective, as we are entering the era of personalized therapy for genetic diseases.File | Dimensione | Formato | |
---|---|---|---|
s41598-022-10220-0.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
1.59 MB
Formato
Adobe PDF
|
1.59 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.